© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
June 08, 2021
The use of IVIG in the treatment of recalcitrant pemphigus vulgaris and foliaceus and bullous pemphigoid is supported by 2 clinical trials.
It is important for health care providers to explain compliance to these regimens to patients, both from a clinical and cost perspective.
June 01, 2021
According to the study authors, 9% of the children receiving the combination therapy did not respond to treatment, compared to 51% of children receiving IVIG alone.
May 27, 2021
Adverse effects from intravenous immunoglobulin tend to be mild, but moderate and severe adverse effects have been observed.
May 20, 2021
Treatment with Hizentra might not be possible if your doctor determines you have hyperprolinemia (too much proline in the blood), or are IgA-deficient with antibodies to IgA and a history of hypersensitivity.
May 10, 2021
Although it is currently used off-label for many neuroinflammatory and neurodegenerative disorders, intravenous immunoglobulin is showing promise for a growing number of neurological diseases.
April 29, 2021
A metanalysis published in SN Comprehensive Clinical Medicine found that administering the therapies early in a patient’s treatment could be associated with better outcomes.
April 16, 2021
The duration for body temperature normalization, oxygen saturation, and mechanical ventilation were significantly shorter for patients who received IVIG in addition to standard of care (SOC) when compared to those only receiving SOC.